The U.S. Food and Drug Administration (FDA) has recently issued a final rule aimed at enhancing our understanding of antimicrobial use in food-producing animals.

This rule focuses on collecting more detailed information about antimicrobial sales and distribution, specifically by species.

Antimicrobials play a crucial role in veterinary medicine, but their use must be judicious to prevent the development of antimicrobial resistance.

The FDA recognizes the importance of monitoring and regulating antimicrobial use in food-producing animals to safeguard public health.

Diagnosis and Monitoring:

The final rule seeks to achieve the following objectives:

Detailed Information: By requiring animal drug sponsors to submit species-specific estimates of antimicrobial sales, the FDA aims to gain a clearer picture of how these drugs are used in major food-producing species (such as cattle, swine, chickens, and turkeys)

Targeted Efforts: Armed with this data, the FDA can better target its efforts to ensure the judicious use of medically important antimicrobials. This means promoting responsible use while minimizing the risk of resistance development.

Effectiveness Measurement: The collected information will also help the FDA assess the effectiveness of its efforts in regulating antimicrobial use.

The final rule includes the following provisions:

Species-Specific Estimates: Animal drug sponsors must provide sales data broken down by species. This means reporting the quantities of antimicrobials sold or distributed for each type of food-producing animal.

Timeliness of Reporting: To improve transparency, the FDA will publish an annual summary report of antimicrobial sales and distribution information by December 31 of the following year. This ensures that stakeholders have access to up-to-date data.

#antimicrobial #resistance #AMR #animaldrug #gmp #verterinary #auditor #leadauditor #gapanalysis #gapassessment #riskanalysis #capa #qa #qc #qms #qualitycompliance #regulatorycompliance

Concept 1: Product and Process Understanding

The journey begins with a deep dive into the product or business process at hand. Whether it’s manufacturing or a regulated business operation, understanding its intricacies is paramount. #Automation control systems play a crucial role in maintaining Critical Process Parameters (#CPPs), ensuring that Critical Quality Attributes (#CQAs) are not just met but exceeded. Documented system requirements and specifications become the north star, illuminating the path to capturing this essential understanding.

Concept 2: Life Cycle Approach

With foundations rooted in product and process comprehension, we transition into the #lifecycleapproach—a systematic journey from planning to retirement of the system. This approach isn’t just about compliance; it’s an odyssey that enhances system quality and effectiveness. Early identification of issues becomes a cornerstone, reducing costs and enhancing efficiency.

Concept 3: Scalable Life Cycle Activities

But no two journeys are alike—the life cycle is not rigid but scalable. It adapts to varying complexities and scopes associated with different computer systems supporting regulated processes. This flexibility ensures that activities align with the risks posed by each unique system.

Concept 4: Science-Based Quality Risk Management

At its core lies science-based quality risk management—a meticulous application of risk assessment throughout the life cycle. Rooted in objective evaluations focusing on patient safety, product quality, and data integrity, this concept ensures that risk management isn’t static but dynamic.

Concept 5: Leverage Supplier Involvement

The final piece of this intricate puzzle involves leveraging supplier involvement—an often-underestimated asset in this journey. By tapping into technical expertise from suppliers who adhere to good engineering practices and robust internal quality management systems, organizations can streamline testing processes while upholding stringent compliance standards.

Together these five concepts weave a comprehensive tapestry for navigating through computer system validation—each thread integral to crafting an effective framework rooted in compliance yet flexible enough to adapt to diverse landscapes

#food#drugs#cosmetcis#medicaldevices#auditor#gapanalaysis#riskanalysis#riskassessment#capa#qms#qa#qc#qualitysystem#qualitycompliance#regulatorycompliance#consultant#pharma#mpharmaceuticals#meidicnalproducts#trendingnow#trendingpost#gamp5#csv#computersystemvalidation#gmp#gxp#IRCA#CQI#leadauditor

What is a Mock Recall?

A mock recall is a simulated exercise conducted by pharmaceutical companies to evaluate the effectiveness of their recall procedures. It involves tracing and retrieving a specific batch of a drug from the market without actually removing it. The goal is to identify any weaknesses in the recall process and to ensure that if a real recall were necessary, it could be executed swiftly and effectively.

Regulatory Framework

It is important for pharmaceutical professionals to consult the specific guidelines and regulations applicable in their region and for their products. The Central Drugs Standard Control Organization(#CDSCO) in India has established guidelines for recalls and rapid alert systems, which include mock recalls. The #EMA coordinates the assessment of reports of product quality defects for centrally authorized medicines in Europe. The #FDA has regulations under 21 CFR Part 7 that cover voluntary and mandatory recalls. The regulations also suggest that companies should conduct mock recalls to ensure that their recall procedures are effective.

Best Practices for Conducting Mock Recalls:

#Frequency: Conduct mock recalls at regular intervals, at least once every two years, to ensure continuous readiness.

#Scope: Include products with the longest distribution chain to test the recall process across all levels of the supply chain.

#Documentation: Keep detailed records of the mock recall process, including the identification of the batch, the distribution path, and the time taken to complete the recall.

#Evaluation: After the mock recall, evaluate the effectiveness of the recall and make necessary adjustments to the recall plan.

Mock recalls are an essential component of a robust quality management system in the pharmaceutical industry. By adhering to the regulations and best practices, pharmaceutical companies can ensure they are prepared to protect public health in the event of a product quality issue.

#food #drugs #cosmetics #medicaldevices #auditor #qualitycontrol #mockrecalls #qualitycompliance #injectables #drugproducts #API #regulatorycompliance #qualityconsultant #regulatoryconsultant #qms #qa #qc #gapanalysis #riskanalysis #capa #remediation #gmp #qms #trendingpost #trendingnow #trendingreels #riskmanagement

Cleaning process validation is a critical aspect of pharmaceutical manufacturing. It ensures that the cleaning procedures employed between different production runs are effective and reliable, minimizing the risk of cross-contamination.

What is Cleaning Process Validation?

Cleaning process validation is a scientific technique that provides documented, risk-based evidence that a typical cleaning method will consistently clean the equipment or a medical device in compliance with its predetermined specifications and quality attributes.

It ensures that previous product traces have been removed, operations are contamination-free, and safe batch-to-batch transitions are possible.

Importance of Cleaning Process Validation:

Cleaning validation is essential for ensuring that the cleaning procedure for pharmaceutical products meets defined safety and accuracy standards. It can also detect possible flaws in the manufacturing process, allowing them to be addressed before they cause major damage to the product.

Proper equipment cleaning during the medicinal product manufacturing process is critical for maintaining product quality, preventing contamination, and ensuring patient safety. Let’s delve into the importance of this process:

Product Integrity Preservation:

High-Value Products: Pharmaceutical products have significant financial value for developers and are crucial for patient treatments.

Contaminant Avoidance: Contaminants must be avoided at all costs to maintain product integrity.

Supply Chain Impact: Insufficient care can lead to contaminants entering the drug product supply chain, resulting in costly failures and potential recalls.

Cross-Contamination Prevention:

Mono-Product Processes: For processes involving a single product, visual inspection alone is often adequate for cleaning validation or verification.

Multi-Product Processes: In multi-product operations, the risk of cross-contamination is higher.

Scientific Approach: Cleaning limits based on a scientific approach (such as Health Based Exposure Limits) must be set.

Shared Equipment Train: These limits should be integrated into the shared equipment train.

Control Alignment: Control levels (including sampling and detection methods) should align with the product type and equipment visibility.

Equipment Cleaning Practices:

Changeover Cleaning:

Equipment used for different products during campaigns should undergo thorough cleaning.

Interval Cleaning:

Regular cleaning during a campaign, as necessary.

Dedicated End-of-Campaign Cleaning:

Ensures equipment is ready for the next batch.

Remember, effective equipment cleaning on direct or indirect product contact surfaces is essential to prevent cross-contamination and maintain product quality throughout the manufacturing process.

Solvent Requirements for Equipment Cleaning Process:

The choice of solvent for the cleaning process is crucial.

The most common and practical solvent is water due to its non-toxicity, cost-effectiveness, and environmental friendliness.

However, in some cases, it may be preferable to use a non-aqueous solvent or a combination of both aqueous and non-aqueous solvents due to the solubility characteristics of the materials. Organic solvents such as methanol, toluene, acetone, and ethyl acetate are also commonly used.

Analytical Test Method Requirements:

Analytical methods used in the cleaning validation process should be validated according to the requirements of regulatory bodies like the FDA and EMA.

The four most common types of analytical methods, each with its own set of validation requirements, are identity tests, quantitative tests for impurity content, limit tests for the control of impurities, and potency tests.

The detection limit for each analytical method should be sufficiently sensitive to detect the established acceptable level of the residue or contaminant.

Procedure for Establishing MACO Values:

Maximum Allowable Carryover (MACO) refers to the acceptable amount of a product that can be carried over from one batch to the next.

The correct calculation of MACO is vital for the integrity and success of the cleaning validation program.

MACO can be calculated using various industry-recognized approaches such as health-based, therapeutic, toxicological, and 10 parts per million (ppm) methods.

For example, one common formula for calculating MACO using Permitted Daily Exposure (PDE) is:

  MACO = {PDE x MBS}/{MDD}

  where:

  MACO: Maximum allowable carryover in mg

  PDE: Permitted daily exposure of the previous product

  MBS: Minimum batch size for the next product in mg

  MDD: Maximum Daily dose of the next product in mg

Limit to Control the Carryover of Residual of Previous Products:

The limit to control the carryover of residual of previous products is established based on the MACO value.

This limit ensures that the amount of residual product left on the equipment after cleaning does not exceed the MACO value.

If the calculated MACO limit is not measurable by validated analytical methods, several options can be considered, such as dedicating the equipment to one product, modifying the parameters of the next manufactured product, modifying the sampling parameters, lowering the rinse volume for rinse sampling, or concentrating the rinse sample.

In conclusion, cleaning process validation is a crucial step in assuring quality during pharmaceutical manufacturing. It helps ensure that the cleaning procedures employed are effective and reliable, thereby minimizing the risk of cross-contamination.

#food #drugs #cosmetics #medicaldevices #medicinalproducts #api #qa #qc #ra #reugulatoryaffairs #qualitycompliance #regulatorycompliance #trendingnow #trendingposts #riskanakysis #gapanalysis #riskassessment #capa #remediation #auditor #leadauditor #irca #cqi #pharamceuticals #industries #clv #amv #cleaningvalidation #analyticalmethodvalidation #csv

#Media Fill, also known as Aseptic Process Simulation (#APS), is a method used to evaluate the capability of #aseptic processing activities.

It involves using a #sterile microbiological growth medium in place of the actual product during the simulation.

This process is designed to mimic the routine aseptic manufacturing process as closely as possible, including all critical manufacturing steps.

The goal of a #MediaFill is to test whether the aseptic procedures are adequate to prevent #microbiologicalcontamination during the actual process.

Media fills may be used to evaluate aseptic #techniques used in the assembly of pre-sterilized components and to qualify operators for aseptic techniques.

A typical Media Fill process involves the following steps:

#Selection of Medium: The nutrient medium should be selected based on the #dosage form of the product and the selectivity, clarity, concentration, and suitability for #sterilization of the nutrient medium.

#Simulation Test: This test should be performed at least annually by each person authorized to compound in a low-risk level environment under conditions that closely simulate the most challenging or stressful conditions encountered during compounding of low-risk level CSPs.

#Incubation Period: The filled containers should be incubated at 20° to 25° or at 30° to 35° for a minimum of 14 days.

#Evaluation: After the incubation period, the containers are inspected for microbial growth.

The target for a Media Fill test should be zero growth. However, the acceptable limits for contaminated units are as follows:

When filling fewer than 5000 units, no contaminated units should be detected.

When filling 5000-10000 units, one contaminated unit should result in an investigation, including consideration of repeat media fill. Two contaminated units are considered cause for #revalidation.

In conclusion, Media Fill is an essential tool in the #pharmaceutical and #biotechnology industries for #validating aseptic #manufacturing processes.

It helps ensure that the aseptic procedures are adequate to prevent #contamination during actual #drug production, thereby ensuring the #safety and #efficacy of the final product.

#food#drugs#cosmetics#medicaldevices#auditor#gmp#glp#qa #qc #qualitycompliance #regulatorycompliance #capa #gapanalysis #remediation #irca #cqi #leadauditor #gapassessment #injectables #drugproducts #medicinalproducts #trendingpost #trendinnews #trendingnow

#MoCRA is a law that expands the #FDA’s authority to regulate #cosmetics in the US. It aims to ensure the safety of cosmetic products that many consumers use daily.

On average, people use 6 to 12 cosmetics products daily, including #makeup, #nailpolishes, #shavingcream and other #grooming products, #perfumes, #face and #bodycleansers, #haircare products, #moisturizers, and other #skincare products.

KEY TERMS IN MoCRA:

Adverse Event: Any health-related event associated with the use of a cosmetic product that is adverse.

Facility: Any establishment (including an establishment of an #importer) that #manufactures or processes cosmetic products distributed in the #UnitedStates.

Responsible Person: The manufacturer, #packer, or #distributor of a cosmetic product whose name appears on the label of such cosmetic product.

Serious Adverse Event: An adverse event that results in serious health consequences.

MoCRA provides new authorities to FDA including:

Records Access

Mandatory Recall Authority

MoCRA establishes the following new requirements for industry:

Adverse Event Reporting: A responsible person is required to report serious adverse events associated with the use of cosmetic products in the United States to FDA within 15 business days.

Facility Registration: Manufacturers and processors must register their facilities with FDA and renew their registration every two years.

Product Listing: A responsible person must list each marketed cosmetic product with FDA, including product ingredients, and provide any updates annually.

Safety Substantiation: Companies and individuals who manufacture or market cosmetics have a responsibility to ensure the safety of their products.

A responsible person is required to ensure and maintain records supporting adequate safety substantiation of their cosmetic products. Manufacturers can use relevant safety data that is already available to support the safety of their products.

Animal testing is not a requirement for marketing a cosmetic product.

MoCRA also requires that industry comply with regulations that FDA will establish for:

Good Manufacturing Practice (#GMP) requirements for facilities that manufacture cosmetic products.

#Fragrance#allergen labeling requirements.

Standardized #testing methods for detecting and identifying asbestos in talc-containing cosmetic products.

#food#drugs#cosmetics#medicaldevices#auditor#leadauditor#facilityregistration#productlisting #responsibleperson #gapanalysis #riskassessment #trendingnow #trendingpost #consultants #qualitycompliance #regulatorycompliance #qa #qc #rq #irca #cqi

For more information, please contact info@fwqrc.com

Active Pharmaceutical Ingredients (#APIs) are the core components of any drug, contributing directly to the treatment or prevention of diseases. The #quality, #safety, and #efficacy of APIs are of paramount importance, necessitating stringent regulatory oversight. In Europe, this is facilitated through a process known as Drug Master Filing (#DMF).

A Drug Master File (DMF) is a confidential, detailed document submitted by API manufacturers to #regulatory authorities. It contains comprehensive information about the API, including its manufacturing process, quality control #procedures, #packaging, and #storage. DMFs enable regulatory authorities to review this information during the approval process of the #drug.

In #Europe, the European Medicines Agency (#EMA) oversees the DMF submission process. The EMA requires the submission of an Active Substance Master File (#ASMF), previously known as a European Drug Master File (EDMF), for APIs.

The ASMF comprises two main parts:
#Applicant’s Part (#AP): Contains non-confidential information about the API that can be shared with the drug product manufacturer. It includes details about the substance’s general properties, manufacturing method, and control of critical steps and intermediates.
#Restricted Part (#RP): Contains confidential information that is not shared with the drug product manufacturer. It includes detailed information about the manufacturing process, validation, and control of materials.

The ASMF procedure involves the following steps:
#Preparation: The API manufacturer prepares the ASMF in accordance with the EMA’s guidelines.
#Submission: The ASMF is submitted to the EMA and the relevant National Competent Authorities (#NCAs). The API manufacturer also provides the drug product manufacturer with the AP.
#Assessment: The EMA and NCAs assess the ASMF as part of the evaluation of the Marketing Authorization Application (#MAA) submitted by the drug product manufacturer.
#Updates: Any changes to the API or its manufacturing process must be updated in the ASMF and submitted to the EMA and NCAs.

The DMF process plays a crucial role in ensuring the quality, safety, and efficacy of APIs. It facilitates transparency between API manufacturers, drug product manufacturers, and regulatory authorities, ultimately safeguarding public health. As such, understanding and correctly implementing this process is vital for API manufacturers seeking to enter the European market.

#FWQRC-GxP & Regulatory Consultant plays a vital role in supporting companies to achieve and maintain compliance, ensuring patient safety and product quality.
#Consultancy Services: FWQRC-GxP provides expert guidance on #GMP compliance, regulatory affairs, and quality management.
#Regulatory Submissions: Prepare and submit regulatory documentation.
#Continuous Improvement: Foster a culture of quality and continuous enhancement.

#gapanalysis #drugs #capa #risk #medicinalproducts #auditing #auditor #leadauditor #trendingpost #riskanalysis

EUGMP Part 1 Requirements

EUGMP Part 1 outlines the basic requirements for medicinal products. These include:

1. Quality Management: The establishment of a robust quality management system is crucial. This includes defining responsibilities, processes, and risk management procedures.
2. Personnel: Adequate number of personnel with necessary qualifications and experience should be employed. Regular training should be provided to ensure they remain updated with the latest regulations.
3. Premises and Equipment: The premises and equipment used should be fit for purpose. They should be designed, located, and maintained to suit the operations to be carried out.
4. Documentation: Detailed records of all procedures and changes should be maintained. This ensures traceability and accountability.
5. Production: The production process should be clearly defined and controlled. All necessary controls should be in place to ensure product quality.
6. Quality Control: Regular quality checks should be conducted. Any deviations from the set standards should be investigated and corrected.

Challenges in Compliance

While the EUGMP guidelines are comprehensive, industries often face challenges in adhering to them. These include:

1. Keeping Up with Regulatory Changes: The regulatory landscape is constantly evolving, making it challenging for industries to stay updated.
2. Resource Constraints: Implementing and maintaining a robust quality management system requires significant resources.
3. Technical Challenges: Ensuring that premises and equipment meet the necessary standards can pose technical challenges.
4. Training Personnel: Regularly training personnel to ensure they are aware of the latest regulations can be time-consuming and costly.

How FWQRC-Global GxP & Regulatory Consultant Can Help

FWQRC-Global GxP & Regulatory Consultant provides support to industries in navigating these challenges. Their services include:

1. Regulatory Updates: They provide regular updates on regulatory changes, helping industries stay compliant.
2. Quality Management System Implementation: They assist in the implementation of a robust quality management system, ensuring compliance with EUGMP regulations.
3. Training: They offer training programs to equip personnel with the necessary knowledge and skills.
4. Audit and Inspection: They conduct audits and inspections to identify areas of non-compliance and suggest corrective actions.

In conclusion, while complying with EUGMP Part 1 requirements can be challenging, with the right support and resources, it is achievable. FWQRC-Global GxP & Regulatory Consultant is committed to helping industries navigate these challenges and ensure compliance with EUGMP regulations.

#food #drugs #cosmetics #medicaldevices #auditing #irca #eugmp

The United States Food and Drug Administration (USFDA) plays a crucial role in ensuring the safety and efficacy of food, drugs, and medical devices. To maintain these standards, the USFDA conducts inspections of manufacturing facilities. For small scale industries, preparing for these inspections can be a daunting task. This is where the FWQRC (Fire Water Quality & Regulatory Consultant) technical team steps in, providing much-needed consultant support.

USFDA Inspection Checklist

The USFDA has a comprehensive inspection guide that covers various sectors including biotechnology, computer issues, devices, drugs, foods & cosmetics, and more. Here are some key elements that are generally included in an FDA inspection:

1. General Information: Basic details such as the facility to be inspected, the date of inspection, the name of the officer in charge, and the inspection location.
2. Administrative: Ensuring proper information dissemination among relevant staff members and a review of Standard Operating Procedures (SOP) for inspections, employee schedules, and clinical equipment.
3. Management Controls: Important procedures related to document/change controls, complaint handling, CAPA, etc.
4. Quality System Overview: Including a Quality Manual if applicable.
5. Organizational Charts & Tables: Job/role descriptions and training protocol/records.

Role of FWQRC Expertise

The FWQRC expertise provides consultant support to small scale industries to help them navigate the complexities of USFDA inspections. While specific services may vary, the support generally includes:

1. Preparation for Inspections: The team helps businesses understand the inspection process and prepare accordingly. This includes reviewing the USFDA inspection checklist and ensuring all necessary documentation and protocols are in place.
2. Training: The team provides training to staff members on how to handle inspections, including what to expect, how to interact with inspectors, and how to respond to potential findings.
3. Post-Inspection Support: After the inspection, the FWQRC team assists with interpreting the results, addressing any issues raised, and implementing corrective actions if necessary.

Conclusion

Navigating USFDA inspections can be challenging, especially for small scale industries. However, with the right preparation and support from experienced consultants like the FWQRC expertise, businesses can confidently face these inspections and ensure they meet the necessary standards. This not only helps in maintaining product quality and safety but also contributes to the overall growth and success of the business.

#food #drugs #cosmetics #medicaldevices #auditing #gmp #consultant #gapanalysis #capa #dmf #eCTD #regulatoryservices #supplierqualification #vendoraudits #trendingnow #trendingposts #trendingnews #irca #leadauditor #fwqrc #usfda #qa #qualityassurance #qualitycontrol #qualitycompliance #qualitymanagement #qms #qc